odesivimab
E468965
Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
All labels observed (2)
| Label | Occurrences |
|---|---|
| odesivimab canonical | 4 |
| atoltivimab | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4784927 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: odesivimab Context triple: [REGN-EB3, hasComponent, odesivimab]
-
A.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
B.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
C.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
D.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
E.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: odesivimab Target entity description: Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
A.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
B.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
C.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
D.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
E.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
- F. None of above. chosen
Statements (20)
| Predicate | Object |
|---|---|
| instanceOf |
monoclonal antibody
ⓘ
therapeutic antibody ⓘ |
| actsOnOrganism | Zaire ebolavirus ⓘ |
| developedAs | component of a monoclonal antibody cocktail ⓘ |
| hasBiologicalRole | antiviral agent ⓘ |
| hasDrugClass | antiviral monoclonal antibody ⓘ |
| hasIndication | Ebola virus infection ⓘ |
| hasMolecularTarget | Ebola virus glycoprotein ⓘ |
| isPartOfRegimen | antibody cocktail for Ebola ⓘ |
| mechanismOfAction | neutralization of Ebola virus via binding to viral glycoprotein ⓘ |
| partOf | antibody cocktail therapy for Ebola virus disease ⓘ |
| routeOfAdministration | intravenous ⓘ |
| targetPathogen |
Ebolavirus
ⓘ
Zaire ebolavirus species ⓘ
linked to:
Zaire ebolavirus
|
| therapeuticArea |
infectious disease
ⓘ
virology ⓘ |
| treatsDisease | Ebola virus disease ⓘ |
| usedFor |
treatment of Ebola virus disease
ⓘ
treatment of Zaire ebolavirus infection ⓘ |
| usedIn | combination therapy for Ebola virus disease ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: odesivimab Description of subject: Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: odesivimab